CAR-T Program(s)
Hematological and Solid Tumors
Pre-clinical / Early ClinicalActive
Key Facts
Indication
Hematological and Solid Tumors
Phase
Pre-clinical / Early Clinical
Status
Active
Company
About Celluris
Celluris is a Swiss-Brazilian biotech startup at the forefront of bringing CAR-T cell therapy to Latin America. As a pioneer in the region, it is developing personalized immunotherapies for a range of cancers by genetically modifying a patient's own T-cells to target tumors. The company has established key research partnerships and is advancing its pipeline, positioning itself to address a significant unmet medical need with potentially transformative treatments. Its strategic location bridges European biotech innovation with the clinical and market opportunities in Brazil.
View full company profileTherapeutic Areas
Other Hematological and Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Disclosed | ONK Therapeutics | Preclinical |
| iNK Platform Programs | Shoreline Biosciences | Pre-clinical |
| CAR-iNKT Programs | MiNK Therapeutics | Preclinical |